Key Highlights

  • Foundayo delivered a 16% reduction in heart attack, stroke, or cardiovascular death risk versus insulin glargine in clinical testing.
  • All-cause mortality decreased by 57% among participants taking the obesity medication during the trial period.
  • The clinical study enrolled 2,700 adults with type 2 diabetes, obesity, and heightened cardiovascular risk factors.
  • Eli Lilly expects to submit an FDA application for Foundayo as a type 2 diabetes therapy before the second quarter of 2026 concludes.
  • Analyst consensus rates LLY as a Strong Buy, with a mean price target of $1,247.38 suggesting potential gains of 31.53%.

Recent developments surrounding Eli Lilly’s Foundayo continue to generate significant interest in the investment community. Following FDA approval for weight management on April 1, fresh clinical trial results have emerged to reinforce the drug’s therapeutic profile.

The advanced-stage study enrolled over 2,700 adult participants and revealed that Foundayo recipients experienced a 16% reduction in combined cardiovascular events—including heart attack, stroke, and cardiovascular death—when compared against those receiving insulin glargine, a commonly prescribed long-acting insulin for diabetes management.

The mortality data proved particularly striking: participants taking Foundayo showed a 57% decrease in death from all causes throughout the study period.


LLY Stock Card
Eli Lilly and Company, LLY

The research population consisted of adults diagnosed with type 2 diabetes who were classified as obese and presented with increased cardiovascular vulnerability. Beyond cardiovascular outcomes, Foundayo demonstrated improvements in A1C measurements—an indicator of long-term blood glucose control—while simultaneously reducing body weight after 52 weeks of treatment. Conversely, participants receiving insulin glargine experienced weight increases.

Lilly announced that the trial achieved its primary endpoints and confirmed plans to pursue FDA approval for Foundayo’s use in type 2 diabetes management. The company intends to utilize the Commissioner’s National Priority Review Voucher to accelerate the regulatory timeline, with submission anticipated by the conclusion of the second quarter in 2026.

Resolving Liver Safety Questions

Regulatory authorities previously requested additional evidence regarding potential hepatic injury associated with the medication. The current trial incorporated specific analysis on this matter and revealed no concerning liver safety signals—findings that align with previous research data.

Trung Huynh from RBC Capital Markets noted that these results should eliminate concerns about Foundayo presenting distinctive liver safety challenges when compared to rival therapies such as Novo Nordisk’s oral Wegovy formulation, which launched in January.

This represents substantial progress for the drug’s commercial outlook. With Novo Nordisk establishing an early presence in the oral obesity treatment market, unresolved safety considerations surrounding Foundayo might have created competitive disadvantages.

Expanding Therapeutic Applications

The cardiovascular findings complement an increasingly diverse clinical profile for the medication. Previous studies have identified potential therapeutic value across multiple conditions, including hypertension management and alcohol dependency.

Financial analysts project that Foundayo could achieve peak annual revenues of $36 billion based on current market assessments.

LLY shares advanced 0.86% following the data announcement. The stock maintains a Strong Buy consensus among 19 Wall Street analysts—comprising 16 Buy recommendations, 2 Hold positions, and 1 Sell rating—with an average price objective of $1,247.38, representing approximately 31.5% appreciation potential from present trading levels.

The diabetes treatment application is scheduled for submission by the end of the second quarter in 2026.